Reason for request
Inclusion on the list of medicines approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit is substantial. |
Clinical Added Value
| important |
In view of the results obtained in a population with an unfavourable prognosis and the size of the effect observed, the Transparency Committee considers that TORISEL provides a substantial improvement in actual benefit (IAB level II) compared with interferon alpha (ROFERON-A) in advanced renal cell carcinoma patients with at least 3 of the 6 prognostic risk factors. |
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
eAt1Sq72YYgnFFP5
